This site is intended for healthcare professionals
Drug information

Mannitol

POM
Read time: 16 mins
Last updated: 29 Sep 2020
Published: 29 Sep 2020

4.1 Therapeutic indications

Mannitol 15% w/v is indicated for use as an osmotic diuretic in the following situations:

• Promotion of diuresis in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible oliguric renal failure becomes established.

• Reduction of intracranial pressure and cerebral oedema, when the blood-barrier is intact.

• Reduction of elevated intraocular pressure when it cannot be lowered by other means.

• Promotion of elimination of renally excreted toxic substances in poisoning.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).